CommercialPrior AuthHigh impact
Onasemnogene Abeparvovec (Zolgensma and Itvisma) (CPB 0953, reviewed 2026-08-10)
Aetna·Genetics, Neurology, Pediatrics·Medical Policy
We identified it
Aug 12, 2026
Summary
Aetna has updated its coverage policy for Onasemnogene Abeparvovec (Zolgensma and Itvisma), gene therapies for spinal muscular atrophy. The policy establishes strict eligibility criteria including age limits, SMN2 gene copy requirements, AAV9 antibody titers, and mandatory precertification. Both medications must be administered at Aetna Institutes GCIT Network facilities, requiring significant workflow changes for billing and prior authorization processes.
Action Required
IMMEDIATE ACTIONS REQUIRED: 1) Billing team must establish mandatory precertification workflow for all Onasemnogene Abeparvovec claims: route all authorization requests to Aetna at (866) 752-7021 or fax (888) 267-3277 using Statement of Medical Necessity (SMN) precertification forms (available via Specialty Pharmacy Precertification). 2) Update billing system to flag that gene and cellular therapies MUST be administered at Aetna Institutes GCIT Network facilities - claims from non-network providers will be denied. 3) Providers must verify member eligibility against specific criteria before treatment: age <2 years for Zolgensma OR age 2-<18 years for Itvisma, SMN2 gene copies ≤3, AAV9 antibody titer ≤1:50 (ELISA), no advanced SMA, no active infections, vaccination status current, and baseline labs (liver function, platelets, troponin I, creatinine) documented. 4) Confirm all prescriptions are from physicians specializing in SMA treatment. 5) Verify discontinuation of competing therapies (Spinraza/nusinersen or Evrysdi) prior to treatment administration. 6) Document that this is single-dose therapy only - repeat administration is not covered. Failure to obtain precertification or use non-network facilities will result in claim denial.